Post by Cytiva

How do you maintain process consistency across a 100x increase in scale?​ Our upstream and viral vector experts, Sara Krekels and Anne MacIntyre, share a side‑by‑side evaluation of AAV5 production across the iCELLis Nano (2.65 m²), iCELLis 50 (33 m²), and iCELLis 500+ (333 m²) fixed‑bed bioreactors.​ Key findings: ​ ✅Comparable pH and metabolite profiles across scales​ ✅Consistent biomass trends and day‑5 cell densities​ ✅Genomic titers averaging ~1×10¹⁰ vg/cm² across all systems​ ✅Majority (~60%) of vector yield captured in the lysate fraction​ These results confirm a practical, predictable path from early development to GMP manufacturing.​ Read the full analysis.